TY - JOUR
T1 - Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022
AU - Barnes, Megan V.C.
AU - Mandla, Anika
AU - Smith, Emma
AU - Maskuniitty, Maija
AU - Openshaw, Peter J.M.
AU - Abo, Yara Natalie
AU - Ascough, Stephanie
AU - Ashwin, Helen
AU - Avirutnan, Panisadee
AU - Catchpole, Andrew P.
AU - Chi, Primus Che
AU - Chiu, Christopher
AU - Darton, Thomas C.
AU - Driciru, Emmanuella
AU - Dula, Dingase
AU - Ferreira, Daniela
AU - Fraser, Alastair
AU - Garrett, Phoebe
AU - Gbesemete, Diane
AU - Gordon, Stephen
AU - Heymann, David L.
AU - Houlder, Emma
AU - Jamrozik, Euzebiusz
AU - Kapulu, Melissa
AU - Kessy, Enock
AU - Overgaard Kildemoes, Anna M.
AU - Koopman, Jan Pieter
AU - McShane, Helen
AU - Navanukroh, Oranich
AU - Osier, Faith H.
AU - Osowicki, Joshua
AU - Pham, Vy
AU - Pollard, Andrew J.
AU - Ratta-Apha, Woraphat
AU - Silk, Sarah E.
AU - Sridhar, Saranya
AU - Swanson, Kena A.
AU - Talaat, Kawsar R.
AU - Thwaites, Ryan S.
AU - Welch, Orly
PY - 2023/10/31
Y1 - 2023/10/31
N2 - HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.
AB - HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.
KW - controlled human infection models
KW - experimental medicine
KW - infectious disease
KW - low-middle-income countries
KW - mucosal immunology
KW - vaccination
U2 - 10.1093/immadv/ltad024
DO - 10.1093/immadv/ltad024
M3 - Review article
SN - 2732-4303
VL - 3
JO - Immunotherapy Advances
JF - Immunotherapy Advances
IS - 1
M1 - ltad024
ER -
